Our HIV research at the IAS 2025 Conference on HIV Science in Kigali
01 Jul 2025
Researchers from the MRC Clinical Trials Unit at UCL, alongside international partners, will present their latest findings on HIV trials at the 13th International AIDS Society (IAS) Conference on HIV Science. The conference will be held in Kigali, Rwanda, and online from Sunday 13 to Thursday 17 July 2025.
Our HIV trials will be featured in both oral presentations and poster sessions at the main IAS conference, as well as at the International Workshop on Pediatrics & HIV 2025, a pre-conference event taking place on Friday 11 and Saturday 12 July.
The IAS Conference is one of the most influential global forums for HIV research, bringing together scientists, policymakers, and advocates to share advances in clinical, basic, and operational HIV science.
A full list of MRC CTU at UCL presentations at both the main conference and pre-conference workshops is available below.
IAS 2025 Conference on HIV Science
|
Date and time (CAT) |
Session |
Title |
Presenter |
|
Wednesday 16 July, 10:45-11:45 AM |
Special issues in paediatrics |
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial |
James Wyncoll |
|
Wednesday 16 July, 3 PM |
Co-Chair's choice |
BREATHER Plus results |
Adeodata R. Kekitiinwa |
International Workshop on Pediatrics & HIV 2025
|
Date and time (CAT) |
Session |
Title |
Presenter |
|
Saturday 12 July, 8:55 AM |
Oral Abstract Presentations III |
Effectiveness and safety of dolutegravir (DTG) in infants and children aged under 12-years at start of DTG in Europe and Thailand
|
Jeannie Collins
|
|
Saturday 12 July, 8:55 AM |
Oral Abstract Presentations III |
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial |
James Wyncoll |
|
Saturday 12 July, 8:55 AM |
Oral Abstract Presentations III |
Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials |
Pauline Amuge |
|
Saturday 12 July, 12:05 PM |
Oral Abstract Presentations IV |
Growth Trajectories Before and After Switching to Dolutegravir in Children Living with HIV in the ODYSSEY Trial
|
Man Chan |
|
Friday 11 July - Saturday 12 July |
Poster number: 86
|
Mortality rates and associated factors among people living with perinatally acquired HIV in Europe and Thailand |
John O’Rourke
|
|
Friday 11 July - Saturday 12 July |
Poster number: 123
|
Growth outcomes in children living with HIV in Europe and Thailand before and after starting dolutegravir
|
Kate Edgar
|
|
Friday 11 July - Saturday 12 July |
Poster number: 26 |
Pregnancies among adolescents and young women on dolutegravir vs standard-of-care in the ODYSSEY trial and effects of the dolutegravir neural tube defect safety alert |
Grace Miriam Ahimbisibwe
|
Further information: